Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Lung Cancer

Free Subscription Articles published in Eur J Cancer Retrieve available abstracts of 115 articles: HTML format

Single Articles

October 2025
1. MERCOLINI F, Sparber-Sauer M, Mascarenhas L, Merks JHM, et al
   Single site metastatic rhabdomyosarcoma: An INternational Soft Tissue saRcoma ConsorTium (INSTRuCT) pooled analysis.
   Eur J Cancer. 2025;229:115793.
   PubMed     Abstract available
   
   
   
2. TSUKAGUCHI A, Matsumoto K, Tamiya A, Tamiya M, et al
   Corrigendum to "Timing of first pembrolizumab infusion and long-term outcomes in non-small cell lung cancer: A retrospective multicenter study" [Eur J Cancer. 2025;228:115748].
   Eur J Cancer. 2025;230:116010.
   PubMed    
   
   
   
3. HOUDA I, Naves D, Ulas EB, Lissenberg-Witte BI, et al
   Survival outcomes with carboplatin versus cisplatin and the impact of COVID-19 on platinum choice: A nationwide Netherlands registry study in small cell lung cancer patients (CACIS).
   Eur J Cancer. 2025;230:116042.
   PubMed     Abstract available
   
   
   September 2025
4. GUO J, Yao W, You Y
   Letter Re: Intercalated avelumab plus platinum-based chemotherapy in patients with extensive-stage small-cell lung cancer (PAVE): Final outcome, immunophenotypic and biomarker analysis of a multi-center phase II Hellenic Cooperative Oncology Group stu
   Eur J Cancer. 2025;230:116023.
   PubMed    
   
   
   
5. WEBENDOERFER M, Wiesweg M, Winantea J, Keyl J, et al
   Early years, advanced disease: The unmet need in young adults with non-small cell lung cancer.
   Eur J Cancer. 2025;230:116011.
   PubMed     Abstract available
   
   
   
6. PRABHASH K, Noronha V, Patil V, Menon N, et al
   Response to Letter Re: "A randomized trial of patient navigation with symptom-monitoring in advanced lung cancer".
   Eur J Cancer. 2025;230:115802.
   PubMed    
   
   
   
7. LIU Y, Wang L, Li L, He L, et al
   Comment on: "A randomized trial of patient navigation with symptom-monitoring in advanced lung cancer".
   Eur J Cancer. 2025;230:115801.
   PubMed    
   
   
   
8. BYUN JY, Kim J, Park S, Sun JM, et al
   A matching-adjusted indirect comparison of first-line lorlatinib and alectinib for the treatment of ALK-rearranged advanced non-small cell lung cancer.
   Eur J Cancer. 2025;230:115805.
   PubMed     Abstract available
   
   
   
9. SHIRAISHI Y, Shimose T, Tachihara M, Tsuchiya-Kawano Y, et al
   Atezolizumab with carboplatin plus nab-paclitaxel combination therapy for TTF-1 negative advanced nonsquamous non-small cell lung cancer: A multicenter, single-arm phase 2 trial (F1NE TUNE, LOGiK 2102).
   Eur J Cancer. 2025;229:115779.
   PubMed     Abstract available
   
   
   
10. MURO K, Feinstein T, Baranda J, Bonta I, et al
    Enfortumab vedotin in patients with advanced non-small cell lung cancer after disease progression on platinum- and PD-1/PD-L1 inhibitor-containing regimens: Phase 2 international multicenter EV-202 study.
    Eur J Cancer. 2025;227:115603.
    PubMed     Abstract available
    
    
    
11. GALLINA FT, Marinelli D, Taje R, Visca P, et al
    TP53 co-mutations increase risk of recurrence in EGFR-mutated stage I lung adenocarcinoma.
    Eur J Cancer. 2025;227:115622.
    PubMed     Abstract available
    
    
    August 2025
12. TSUKAGUCHI A, Matsumoto K, Tamiya A, Tamiya M, et al
    Timing of first pembrolizumab infusion and long-term outcomes in non-small cell lung cancer: A retrospective multicenter study.
    Eur J Cancer. 2025;228:115748.
    PubMed     Abstract available
    
    
    
13. ITALIANO A, Gautier O, Dupont J, Assi T, et al
    The correlation of liquid biopsy genomic data to radiomics in colon, pancreatic, lung and prostatic cancer patients.
    Eur J Cancer. 2025;226:115609.
    PubMed     Abstract available
    
    
    
14. YAMAGUCHI K, Takao S, Kanaji N, Hirakawa T, et al
    The clinical potential of HMGB1 for the risk assessment of severe checkpoint inhibitor pneumonitis: A prospective multicenter study (CS-Lung004).
    Eur J Cancer. 2025;226:115606.
    PubMed     Abstract available
    
    
    
15. PRABHASH K, Noronha V, Patil V, Menon N, et al
    A randomized trial of patient navigation with symptom-monitoring in advanced lung cancer.
    Eur J Cancer. 2025;228:115730.
    PubMed     Abstract available
    
    
    
16. NAGASHIMA H, Fukuhara T, Utsumi Y, Suzuki A, et al
    A phase II study of afatinib in combination with pemetrexed and carboplatin in patients with EGFR mutation-positive non-squamous, advanced non-small cell lung cancer (NSCLC) refractory to first-line osimertinib treatment: NEJ025B study.
    Eur J Cancer. 2025;229:115693.
    PubMed     Abstract available
    
    
    July 2025
17. MONACA F, Gomez-Randulfe I, Walls G, Cantale O, et al
    Consolidation thoracic radiotherapy after chemoimmunotherapy in ES-SCLC: A multicentric retrospective analysis.
    Eur J Cancer. 2025;225:115592.
    PubMed     Abstract available
    
    
    
18. GOBBINI E, Langlais A, Missy P, Chanoine S, et al
    Morphine and metformin impact immunotherapy benefit in patients with NSCLC: Results of the real-world study IFCT-1502 CLINIVO-SNDS.
    Eur J Cancer. 2025;225:115560.
    PubMed     Abstract available
    
    
    
19. YIP R, Mulshine JL, Oudkerk M, Field J, et al
    Current evidence of low-dose CT screening benefit.
    Eur J Cancer. 2025;225:115570.
    PubMed     Abstract available
    
    
    
20. LINARDOU H, Papadopoulou K, Korfiatis N, Goussia A, et al
    Intercalated Avelumab plus platinum-based chemotherapy in patients with Extensive-Stage Small-Cell Lung cancer (PAVE): Final outcome, immunophenotypic and biomarker analysis of a multi-center phase II Hellenic Cooperative Oncology Group study.
    Eur J Cancer. 2025;228:115660.
    PubMed     Abstract available
    
    
    
21. PARK GH, Park S, Kim H, Jung HA, et al
    Prospective investigation of biomarker and resistance mechanism using longitudinal cell-free NGS in non-small cell lung cancer with EGFR exon 20 insertion treated with amivantamab.
    Eur J Cancer. 2025;226:115631.
    PubMed     Abstract available
    
    
    
22. ALEXANDER M, Cheng Y, Lee SH, Passaro A, et al
    Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated non-small cell lung cancer: Patient satisfaction and resource utilization results from the PALOMA-3 study.
    Eur J Cancer. 2025;227:115624.
    PubMed     Abstract available
    
    
    
23. RECK M, Paz-Ares LG
    Response to the letter Re: "Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial".
    Eur J Cancer. 2025;226:115610.
    PubMed    
    
    
    
24. KUSCHE H, Gundler C, Johanns O, Sauerberg M, et al
    Leveraging machine-learning techniques to detect recurrences in cancer registry data: A multi-registry validation study using German lung cancer data.
    Eur J Cancer. 2025;227:115604.
    PubMed     Abstract available
    
    
    
25. SCATTOLIN D, Dingemans AC, Maso AD, Guarneri V, et al
    Outcome and safety of lurbinectedin as compassionate use in extensive stage small cell lung cancer: A multicentric international cohort.
    Eur J Cancer. 2025;226:115595.
    PubMed     Abstract available
    
    
    June 2025
26. O'REILLY D, O'Grady A, Hayes C, Piggott L, et al
    Clinical benefit and cost of plasma-first next-generation sequencing in patients with newly diagnosed advanced non-small cell lung cancer in Ireland: The PLAN study.
    Eur J Cancer. 2025;225:115582.
    PubMed     Abstract available
    
    
    
27. LAGUNA JC, Moreno L, Potrony M, Grau E, et al
    Prevalence and characteristics of lung cancer in families harboring Pathogenic Germline Variants in cancer predisposing genes: A 20-year retrospective analysis.
    Eur J Cancer. 2025;225:115571.
    PubMed     Abstract available
    
    
    May 2025
28. MONACA F, Gomez-Randulfe I, Parreira AS, Longo V, et al
    Correlation between irAEs and survival outcomes in patients with ES-SCLC treated with first-line chemoimmunotherapy.
    Eur J Cancer. 2025;221:115435.
    PubMed     Abstract available
    
    
    
29. AIGNER C, Baldes N, Begic M, Doerr F, et al
    Current perspective on resectability in stage III locally advanced NSCLC - The thoracic surgeons' view.
    Eur J Cancer. 2025;221:115426.
    PubMed     Abstract available
    
    
    
30. VAN KESSEL E, Woerdman N, Pluim D, Kerklaan BM, et al
    Added prognostic value of circulating tumor cell numbers in CSF of patients with leptomeningeal metastasis from epithelial tumors.
    Eur J Cancer. 2025;220:115377.
    PubMed     Abstract available
    
    
    
31. GRAUS MUJE, van Diepen AE, Josemanders K, Besselink MG, et al
    Patterns of disease dissemination and survival in patients with synchronous and metachronous metastatic pancreatic adenocarcinoma: Nationwide population-based study.
    Eur J Cancer. 2025;220:115385.
    PubMed     Abstract available
    
    
    April 2025
32. AGRAWAL M, Surendran AK, Biswas R
    Letter Re: Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial.
    Eur J Cancer. 2025 Apr 23:115442. doi: 10.1016/j.ejca.2025.115442.
    PubMed    
    
    
    
33. KIM S, Ahn Y, Lee GD, Choi S, et al
    Validation of the 9th Tumor, Node, and Metastasis Staging System for Patients with Surgically Resected Non-Small Cell Lung Cancer.
    Eur J Cancer. 2025;222:115436.
    PubMed     Abstract available
    
    
    March 2025
34. CORTIULA F, Kutiel TS, Hsu ML, Hendriks LEL, et al
    Comparative efficacy of immunotherapy-based treatment versus chemotherapy-only in patients with unresectable NSCLC with disease progression post chemoradiation and durvalumab.
    Eur J Cancer. 2025;219:115302.
    PubMed     Abstract available
    
    
    
35. SALVESTRINI V, Bonaparte I, Becherini C, Desideri I, et al
    Stereotactic body radiotherapy for lung-only oligometastatic head and neck squamous cell carcinoma: Long-term clinical outcome and favorable predictive factors.
    Eur J Cancer. 2025;218:115260.
    PubMed     Abstract available
    
    
    
36. MULSHINE JL, Avila RS, Sylva M, Aldige C, et al
    AI integrations with lung cancer screening: Considerations in developing AI in a public health setting.
    Eur J Cancer. 2025;220:115345.
    PubMed     Abstract available
    
    
    February 2025
37. WANG HY, Liao WY, Ho CC, Wu SG, et al
    Enhanced detection of actionable mutations in NSCLC through pleural effusion cell-free DNA sequencing: A prospective study.
    Eur J Cancer. 2025;217:115224.
    PubMed     Abstract available
    
    
    
38. LANCASTER HL, Jiang B, Davies MPA, Gratama JWC, et al
    Histological proven AI performance in the UKLS CT lung cancer screening study: Potential for workload reduction.
    Eur J Cancer. 2025;220:115324.
    PubMed     Abstract available
    
    
    
39. LANCASTER HL, Walstra ANH, Myers K, Avila RS, et al
    Action plan for an international imaging framework for implementation of global low-dose CT screening for lung cancer.
    Eur J Cancer. 2025;220:115323.
    PubMed     Abstract available
    
    
    
40. HAN R, Guo H, Shi J, Wang H, et al
    Corrigendum to "Tumour microenvironment changes after osimertinib treatment resistance in non-small cell lung cancer" [Eur J Cancer 189 (2023) 112919].
    Eur J Cancer. 2025 Feb 20:115307. doi: 10.1016/j.ejca.2025.115307.
    PubMed    
    
    
    
41. WALSTRA ANH, Lancaster HL, Heuvelmans MA, van der Aalst CM, et al
    Corrigendum to: Feasibility of AI as first reader in the 4-IN-THE-LUNG-RUN lung cancer screening trial: Impact on negative-misclassifications and clinical referral rate, European Journal of Cancer, Volume 216, 5 February 2025, 115214.
    Eur J Cancer. 2025;218:115294.
    PubMed    
    
    
    
42. WISLEZ M, Mascaux C, Cadranel J, Thomas QD, et al
    Real-world effectiveness and tolerability of sotorasib in patients with KRAS G12C-mutated metastatic non-small cell lung cancer: The IFCT-2102 Lung KG12Ci study.
    Eur J Cancer. 2025;219:115301.
    PubMed     Abstract available
    
    
    
43. BORG M, Lokke A, Ibsen R, Hilberg O, et al
    Four decades of lung cancer: Trends in comorbidities and causes of death in a nationwide Danish cohort.
    Eur J Cancer. 2025;218:115303.
    PubMed     Abstract available
    
    
    
44. YANKELEVITZ DF, Yip R, Jirapatnakul A, Henschke CI, et al
    The Winner and still champion: Nodule volume doubling times.
    Eur J Cancer. 2025;216:115184.
    PubMed     Abstract available
    
    
    January 2025
45. MULSHINE JL, Pyenson B, Healton C, Aldige C, et al
    Paradigm shift in early detection: Lung cancer screening to comprehensive CT screening.
    Eur J Cancer. 2025;218:115264.
    PubMed     Abstract available
    
    
    
46. ACKER F, Reck M, Martin D, Rieken S, et al
    Efficacy and safety of immune checkpoint inhibition combined with concurrent chemoradiotherapy in patients with stage III unresectable non-small cell lung cancer: A systematic review and meta-analysis.
    Eur J Cancer. 2025;218:115266.
    PubMed     Abstract available
    
    
    
47. LAKTIONOV K, Smolin A, Stroyakovskiy D, Moiseenko V, et al
    Prolgolimab with chemotherapy as first-line treatment for advanced non-squamous non-small-cell lung cancer.
    Eur J Cancer. 2025;217:115255.
    PubMed     Abstract available
    
    
    
48. SAAL J, Eckstein M, Ritter M, Brossart P, et al
    The modified Glasgow Prognostic Score (mGPS) can guide decisions for immunotherapy treatment beyond progression.
    Eur J Cancer. 2025;215:115163.
    PubMed     Abstract available
    
    
    
49. HONG TH, Hwang S, Abbosh C, Dasgupta A, et al
    Association of pre-surgical circulating tumor DNA detection, use of sublobar resection with risk of recurrence in stage I non-small cell lung cancer.
    Eur J Cancer. 2025;217:115237.
    PubMed     Abstract available
    
    
    December 2024
50. WALSTRA ANH, Lancaster HL, Heuvelmans MA, van der Aalst CM, et al
    Feasibility of AI as first reader in the 4-IN-THE-LUNG-RUN lung cancer screening trial: impact on negative-misclassifications and clinical referral rate.
    Eur J Cancer. 2024;216:115214.
    PubMed     Abstract available
    
    
    
51. LEE SM, Hewish M, Ahmed S, Papadatos-Pastos D, et al
    Hydroxychloroquine in combination with platinum doublet chemotherapy as first-line treatment for extensive-stage small cell lung cancer (Study 15): A randomised phase II multicentre trial.
    Eur J Cancer. 2024;215:115162.
    PubMed     Abstract available
    
    
    
52. TANAKA H, Makiguchi T, Tozuka T, Kawashima Y, et al
    Comparison of immune checkpoint inhibitor plus chemotherapy or ipilimumab plus nivolumab-based therapy for NSCLC patients with PD-L1 TPS (1-49 %): TOPGAN2023-01.
    Eur J Cancer. 2024;213:115117.
    PubMed     Abstract available
    
    
    November 2024
53. PATEL AJ, Hemead H, Law J, Wali A, et al
    Impact of the timing of immunotherapy administration on overall survival for resectable non-small cell lung cancer (iACORN study): A systematic review and meta-analysis of randomised trials.
    Eur J Cancer. 2024;214:115118.
    PubMed     Abstract available
    
    
    
54. ALSHAMMARI A, Patel A, Boyle M, Proli C, et al
    Prevalence of invasive lung cancer in pure ground glass nodules less than 30 mm: A systematic review.
    Eur J Cancer. 2024;213:115116.
    PubMed     Abstract available
    
    
    
55. DERNBACH G, Kazdal D, Ruff L, Alber M, et al
    Dissecting AI-based mutation prediction in lung adenocarcinoma: A comprehensive real-world study.
    Eur J Cancer. 2024;211:114292.
    PubMed     Abstract available
    
    
    
56. VELUT Y, Arque B, Wislez M, Blons H, et al
    The tumor immune microenvironment of SCLC is not associated with its molecular subtypes.
    Eur J Cancer. 2024;212:115067.
    PubMed     Abstract available
    
    
    
57. ZHOU Q, Yang N, Zhao M, Huang D, et al
    Potent covalent irreversible inhibitor of KRAS G12C IBI351 in patients with advanced solid tumors: First-in-human phase I study.
    Eur J Cancer. 2024;212:114337.
    PubMed     Abstract available
    
    
    October 2024
58. SAALFELD FC, Moller J, Christopoulos P, Wenzel C, et al
    Small cell transformation in EGFR-mutated non-small cell lung cancer: DLL3 expression and efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with chemotherapy.
    Eur J Cancer. 2024;213:115065.
    PubMed     Abstract available
    
    
    
59. LEONETTI A, Perrone F, Puntoni M, Maglietta G, et al
    Response to the Letter re: Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed.
    Eur J Cancer. 2024 Oct 2:115057. doi: 10.1016/j.ejca.2024.115057.
    PubMed    
    
    
    September 2024
60. BENJAMIN DJ, Prasad V
    Inadequate staging and excessive surveillance imaging: Evaluating the magnitude of benefit of targeted therapies in lung cancer.
    Eur J Cancer. 2024;212:115058.
    PubMed     Abstract available
    
    
    
61. TSUCHIYA-KAWANO Y, Shiraishi Y, Tanaka K, Tachihara M, et al
    Nivolumab plus ipilimumab with chemotherapy for non-small cell lung cancer with untreated brain metastases: A multicenter single-arm phase 2 trial (NIke, LOGiK 2004).
    Eur J Cancer. 2024;212:115052.
    PubMed     Abstract available
    
    
    
62. RECK M, Granados ALO, de Marinis F, Meyers O, et al
    Patient-reported outcomes in patients with metastatic non-squamous non-small cell lung cancer from the randomized Phase II PERLA trial comparing first-line chemotherapy plus dostarlimab or pembrolizumab.
    Eur J Cancer. 2024;212:115050.
    PubMed     Abstract available
    
    
    
63. KANG H, Do W, Ahn YC, Chie EK, et al
    A new proposal of simplified classification of non-small cell lung cancer oligometastases for easy applicability through systematic literature analysis and meta-analysis validation.
    Eur J Cancer. 2024;212:115043.
    PubMed     Abstract available
    
    
    
64. JIANG B, Han D, van der Aalst CM, Lancaster HL, et al
    Lung cancer volume doubling time by computed tomography: A systematic review and meta-analysis.
    Eur J Cancer. 2024;212:114339.
    PubMed     Abstract available
    
    
    
65. HOCHMAIR MJ, Vermaelen K, Mountzios G, Carcereny E, et al
    Sotorasib (960 mg or 240 mg) once daily in patients with previously treated KRAS G12C-mutated advanced NSCLC.
    Eur J Cancer. 2024;208:114204.
    PubMed     Abstract available
    
    
    
66. NIKOLAOU V, Gerochristou M, Sgontzou T, Silaidi C, et al
    Beneath the surface: Novel insights into Amivantamab-induced acneiform rash.
    Eur J Cancer. 2024;208:114198.
    PubMed    
    
    
    
67. XIE M, Chu T, Dong X, Wang H, et al
    Heterogeneity in advanced pulmonary sarcomatoid carcinoma and its efficacy to immune checkpoint inhibitors.
    Eur J Cancer. 2024;209:114260.
    PubMed     Abstract available
    
    
    
68. BAUM P, Cardoso R, Lenzi J, Damhuis RAM, et al
    An International Registry Study of Early-Stage NSCLC treatment variations (LUCAEUROPE) in Europe and the USA highlighting variations.
    Eur J Cancer. 2024;209:114233.
    PubMed     Abstract available
    
    
    August 2024
69. RECK M, Ciuleanu TE, Schenker M, Bordenave S, et al
    Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial.
    Eur J Cancer. 2024;211:114296.
    PubMed     Abstract available
    
    
    
70. FALCHERO L, Meyer N, Molinier O, Al Freijat F, et al
    Real-life nationwide characteristics and outcomes of small cell lung cancer over the last 20 years: Impact of immunotherapy on overall survival in a real-life setting.
    Eur J Cancer. 2024;210:114277.
    PubMed     Abstract available
    
    
    
71. LIU SY, Erazo T, Jee J, Arfe A, et al
    Optimal systemic treatment and real-world clinical application of ctDNA in patients with metastatic HER2-mutant lung cancer.
    Eur J Cancer. 2024;210:114257.
    PubMed     Abstract available
    
    
    
72. ZHU H, Wang FL, Liu JR
    Letter Re: Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed.
    Eur J Cancer. 2024 Aug 8:114267. doi: 10.1016/j.ejca.2024.114267.
    PubMed    
    
    
    
73. KRON A, Scheffler M, Wiesweg M, Hummel HD, et al
    Indirect comparison of capmatinib treatment from GEOMETRY mono-1 trial to SOC in German patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutations.
    Eur J Cancer. 2024;207:114158.
    PubMed     Abstract available
    
    
    
74. TOUBLANC AC, Faure M, Verdy G, Rabeau A, et al
    Prospective cardiovascular events in patients with advanced thoracic cancer treated with immune checkpoint inhibitor.
    Eur J Cancer. 2024;207:114191.
    PubMed     Abstract available
    
    
    July 2024
75. DE NIJS K, de Koning HJ, van der Aalst C, Ten Haaf K, et al
    Medical costs of lung cancer by stage, histology and first-line treatment modality in the Netherlands (2012-2021).
    Eur J Cancer. 2024;208:114231.
    PubMed     Abstract available
    
    
    
76. PARK S, Park S, Kim TM, Kim S, et al
    Resistance mechanisms of EGFR tyrosine kinase inhibitors, in EGFR exon 20 insertion-mutant lung cancer.
    Eur J Cancer. 2024;208:114206.
    PubMed     Abstract available
    
    
    
77. DE JAGER VD, Cajiao Garcia BN, Kuijpers CCHJ, de Bock GH, et al
    Regional differences in predictive biomarker testing rates for patients with metastatic NSCLC in the Netherlands.
    Eur J Cancer. 2024;205:114125.
    PubMed     Abstract available
    
    
    
78. REBUZZI SE, Fornarini G, Banna GL, Rescigno P, et al
    Letter comments on: Validation of the Lung Immune Prognostic Index (LIPI) as a prognostic biomarker in metastatic renal cell carcinoma.
    Eur J Cancer. 2024;205:114097.
    PubMed    
    
    
    June 2024
79. ANDERSEN L, Kisistok J, Henriksen TV, Bramsen JB, et al
    Exploring the biology of ctDNA release in colorectal cancer.
    Eur J Cancer. 2024;207:114186.
    PubMed     Abstract available
    
    
    
80. KUBOTA S, Taki T, Miyoshi T, Tane K, et al
    Prognostic value of the international association for the study of lung cancer grading system and its association with the tumor microenvironment in stage I EGFR-muted lung adenocarcinoma.
    Eur J Cancer. 2024;207:114184.
    PubMed     Abstract available
    
    
    
81. FELIP E, Metro G, Soo RA, Wolf J, et al
    Capmatinib plus nazartinib in patients with EGFR-mutated non-small cell lung cancer.
    Eur J Cancer. 2024;208:114182.
    PubMed     Abstract available
    
    
    
82. CARRIL-AJURIA L, Lavaud P, Dalban C, Negrier S, et al
    Validation of the Lung Immune Prognostic Index (LIPI) as a prognostic biomarker in metastatic renal cell carcinoma.
    Eur J Cancer. 2024;204:114048.
    PubMed     Abstract available
    
    
    May 2024
83. LUKE JJ, Long GV, Robert C, Carlino MS, et al
    Safety of pembrolizumab as adjuvant therapy in a pooled analysis of phase 3 clinical trials of melanoma, non-small cell lung cancer, and renal cell carcinoma.
    Eur J Cancer. 2024;207:114146.
    PubMed     Abstract available
    
    
    
84. BLASI M, Kuon J, Luders H, Misch D, et al
    Corrigendum to "First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutations" [Eur J Cancer 199 (2024) 113556].
    Eur J Cancer. 2024 May 24:114130. doi: 10.1016/j.ejca.2024.114130.
    PubMed    
    
    
    
85. LAM M, Olivier T, Haslam A, Tuia J, et al
    Cisplatin shortage results in substitution of more expensive treatments: Drug cost analysis.
    Eur J Cancer. 2024;202:114019.
    PubMed    
    
    
    
86. HERTZ DL, Joerger M, Bang YJ, Mathijssen RH, et al
    Paclitaxel therapeutic drug monitoring - International association of therapeutic drug monitoring and clinical toxicology recommendations.
    Eur J Cancer. 2024;202:114024.
    PubMed     Abstract available
    
    
    
87. CAO H, Ma Z, Huang Q, Han H, et al
    Clinicopathologic features, concurrent genomic alterations, and clinical outcomes of patients with KRAS G12D mutations in resected lung adenocarcinoma.
    Eur J Cancer. 2024;202:113985.
    PubMed     Abstract available
    
    
    
88. HAAKENSEN VD, Ojlert AK, Thunold S, Farooqi S, et al
    UV1 telomerase vaccine with ipilimumab and nivolumab as second line treatment for pleural mesothelioma - A phase II randomised trial.
    Eur J Cancer. 2024;202:113973.
    PubMed     Abstract available
    
    
    April 2024
89. KATSUMATA S, Shimokawa M, Hamada A, Haratake N, et al
    Impact of central nervous system metastasis after complete resection of lung adenocarcinomas harboring common EGFR mutation - A real-world database study in Japan: The CReGYT-01 EGFR study.
    Eur J Cancer. 2024;201:113951.
    PubMed     Abstract available
    
    
    March 2024
90. LEONETTI A, Perrone F, Puntoni M, Maglietta G, et al
    Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed.
    Eur J Cancer. 2024;202:114006.
    PubMed     Abstract available
    
    
    
91. CATOZZI S, Assaad S, Delrieu L, Favier B, et al
    Early morning immune checkpoint blockade and overall survival of patients with metastatic cancer: An In-depth chronotherapeutic study.
    Eur J Cancer. 2024;199:113571.
    PubMed     Abstract available
    
    
    
92. BRAHMER JR, Long GV, Hamid O, Garon EB, et al
    Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients.
    Eur J Cancer. 2024;199:113530.
    PubMed     Abstract available
    
    
    
93. WANG M, Wang T, Shan J, Sun Y, et al
    Alectinib induced vitiligo with rapid re-pigmentation.
    Eur J Cancer. 2024;200:113582.
    PubMed    
    
    
    
94. GOMEZ-RANDULFE I, Leporati R, Gupta B, Liu S, et al
    Recent advances and future strategies in first-line treatment of ES-SCLC.
    Eur J Cancer. 2024;200:113581.
    PubMed     Abstract available
    
    
    February 2024
95. STRATMANN JA, Althoff FC, Doebel P, Rauh J, et al
    Sotorasib in KRAS G12C-mutated non-small cell lung cancer: A multicenter real-world experience from the compassionate use program in Germany.
    Eur J Cancer. 2024;201:113911.
    PubMed     Abstract available
    
    
    
96. MARK M, Froesch P, Gysel K, Rothschild SI, et al
    First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17.
    Eur J Cancer. 2024;200:113600.
    PubMed     Abstract available
    
    
    
97. EBSTEIN E, Brocard P, Soussi G, Khoury R, et al
    Burden of comorbidities: Osteoporotic vertebral fracture during non-small cell lung cancer - the BONE study.
    Eur J Cancer. 2024;200:113604.
    PubMed     Abstract available
    
    
    
98. CHIANG Y, Lu LF, Tsai CL, Tsai YC, et al
    C-C chemokine receptor 4 (CCR4)-positive regulatory T cells interact with tumor-associated macrophages to facilitate metastatic potential after radiation.
    Eur J Cancer. 2024;198:113521.
    PubMed     Abstract available
    
    
    January 2024
99. BLASI M, Kuon J, Luders H, Misch D, et al
    First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutations.
    Eur J Cancer. 2024;199:113556.
    PubMed     Abstract available
    
    
    
100. OLIVIER T, Addeo A
     Shrinking sample sizes in lung cancer trials: Various explanations, open questions.
     Eur J Cancer. 2024;199:113527.
     PubMed    
     
     
     
101. JANKU F, Kim TM, Iyer G, Spreafico A, et al
     First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations.
     Eur J Cancer. 2024;196:113458.
     PubMed     Abstract available
     
     
     
102. BELDERBOS RA, Corneth OBJ, Dumoulin D, Hendriks RW, et al
     Atypical B cells (CD21-CD27-IgD-) correlate with lack of response to checkpoint inhibitor therapy in NSCLC.
     Eur J Cancer. 2024;196:113428.
     PubMed     Abstract available
     
     
     
103. DE MIGUEL-PEREZ D, Pickering EM, Malapelle U, Grier W, et al
     Genomic profiling of tissue and blood predicts survival outcomes in patients with resected pleural mesothelioma.
     Eur J Cancer. 2024;196:113457.
     PubMed     Abstract available
     
     
     
104. SCHALLENBERG S, Dernbach G, Dragomir MP, Schlachtenberger G, et al
     TTF-1 status in early-stage lung adenocarcinoma is an independent predictor of relapse and survival superior to tumor grading.
     Eur J Cancer. 2024;197:113474.
     PubMed     Abstract available
     
     
     
105. WATANABE S, Furuya N, Nakamura A, Shiihara J, et al
     A phase II study of atezolizumab with bevacizumab, carboplatin, and paclitaxel for patients with EGFR-mutated NSCLC after TKI treatment failure (NEJ043 study).
     Eur J Cancer. 2024;197:113469.
     PubMed     Abstract available
     
     
     December 2023
106. STEMMER A, Margalit O, Serpas V, Strauss G, et al
     Immunotherapy in mismatch repair-deficient metastatic colorectal cancer - Outcome and novel predictive markers.
     Eur J Cancer. 2023;198:113495.
     PubMed     Abstract available
     
     
     
107. REMON J, Lopez A, Planchard D, Besse B, et al
     Are we ready to escalate or de-escalate immune treatment strategies in NSCLC based on liquid biopsy data?
     Eur J Cancer. 2023;195:113369.
     PubMed    
     
     
     
108. BOSI C, Bartha A, Galbardi B, Notini G, et al
     Pan-cancer analysis of antibody-drug conjugate targets and putative predictors of treatment response.
     Eur J Cancer. 2023;195:113379.
     PubMed     Abstract available
     
     
     November 2023
109. WENG PC, Huang YL, Cheng CY
     Osimertinib-induced urticarial vasculitis in a patient with lung cancer: A rare cutaneous toxicity.
     Eur J Cancer. 2023;196:113432.
     PubMed    
     
     
     
110. FAKIH M, Wang C, Sandhu J, Ye J, et al
     Immunotherapy response in microsatellite stable metastatic colorectal cancer is influenced by site of metastases.
     Eur J Cancer. 2023;196:113437.
     PubMed     Abstract available
     
     
     
111. RATAIN MJ, Strohbehn GW
     Combining atezolizumab 1200 mg with bevacizumab 15 mg/kg: based on science or just revenues?
     Eur J Cancer. 2023;194:113349.
     PubMed     Abstract available
     
     
     October 2023
112. NUCCIO A, Viscardi G, Salomone F, Servetto A, et al
     Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: Impact of clinicopathological factors and indirect comparison between treatment strategi
     Eur J Cancer. 2023;195:113404.
     PubMed     Abstract available
     
     
     
113. YAMADA T, Goto Y, Tanaka H, Kimura H, et al
     A phase 2 trial of durvalumab treatment following radiation monotherapy in patients with non-small cell lung cancer ineligible for stage III chemoradiotherapy: The SPIRAL-RT study.
     Eur J Cancer. 2023;195:113373.
     PubMed     Abstract available
     
     
     
114. LEARY A, Oaknin A, Trigo JM, Moreno V, et al
     Pooled Safety Analysis of Single-Agent Lurbinectedin in Patients With Advanced Solid Tumours.
     Eur J Cancer. 2023;192:113259.
     PubMed     Abstract available
     
     
     August 2023
115. YANG CY, Shih JY, Liao WY, Ho CC, et al
     Upfront liquid next-generation sequencing in treatment-naive advanced non-small cell lung cancer patients: A prospective randomised study in the Taiwanese health system.
     Eur J Cancer. 2023;193:113310.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.